BioSpace News Archive

Drug Development

XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology

The publication highlights the efficacy of MABp1, in which the study’s primary endpoint was met in 60% of MABp1 treated patients compared to 10% of placebo patients.

December 4, 2017

·

5 min read

Business

CymaBay Therapeutics Strengthens Management Team With Appointment of Paul Quinlan as General Counsel

As CymaBay’s chief legal officer, he will be responsible for all legal affairs, including providing legal advice to CymaBay’s Board of Directors and senior management.

December 4, 2017

·

2 min read

Business

Alligator Bioscience Expands Management Team

Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients.

December 4, 2017

·

2 min read

FDA

Merck’s Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting MS in Canada

MAVENCLAD is the first and only oral short-course treatment to provide efficacy across key measures of disease activity in patients with RRMS.

December 4, 2017

·

5 min read

Drug Development

Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase III Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults

Company remains on track to report topline results in Spring 2018.

December 4, 2017

·

7 min read

Moffitt Cancer Center Treats First U.S. Patient With Newly FDA-Approved CAR-T Therapy

As commercial use for Yescarta gets underway, Moffitt is actively enrolling eligible patients, with ten individuals awaiting treatment.

December 4, 2017

·

3 min read

Genetown

Akili Achieves Primary Efficacy Endpoint in Pediatric ADHD Pivotal Trial

AKL-T01 was shown to be safe in this study, with no serious adverse events observed.

December 4, 2017

·

9 min read

Drug Development

Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis

The FDA’s designation of SER-287 follows a review of data which established a medically plausible basis for the use of SER-287.

December 4, 2017

·

6 min read

Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017

Spectrum Pharmaceuticals announced key presentations of clinical and scientific data related to its products at the 59th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 9-12, 2017.

December 4, 2017

·

6 min read

Biogen Poaches Merck Exec to Lead New Marketing Te

Business

Biogen Continues Bulking Up Its C-Suite With Appointment of Ex-Takeda Exec as CIO

Mr. Hernon joins Biogen with more than 30 years of experience in IT and strategic leadership.

December 4, 2017

·

4 min read